BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/9/2026 6:58:25 AM | Browse: 0 | Download: 0
 |
Received |
|
2025-12-03 00:53 |
|
Peer-Review Started |
|
2025-12-03 08:45 |
|
First Decision by Editorial Office Director |
|
2026-01-08 05:32 |
|
Return for Revision |
|
2026-01-08 05:32 |
|
Revised |
|
2026-01-16 04:05 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-01-27 02:37 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-01-27 06:51 |
|
Articles in Press |
|
2026-01-27 06:51 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-06-29 13:50 |
|
Publish the Manuscript Online |
|
2026-07-09 06:58 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Physiology |
| Manuscript Type |
Correspondence |
| Article Title |
Is the cellular attribution of liraglutide action in diabetic cardiomyopathy conclusive?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ke Su, Pei-Yan Cao, Gan Chen and Ke Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ke Wu, Assistant Professor, MD, PhD, Investigator, Institute for Advanced Biomedical Research, Charles R. Drew University of Medicine and Science, 1731 E. 120th Street, Los Angeles, California 90059, United States. kewu@cdrewu.edu |
| Key Words |
Diabetic cardiomyopathy; Liraglutide; Glucagon-like peptide-1 receptor; Cardiomyocyte; Endothelial cells; Cell-type specificity |
| Core Tip |
The cellular targets mediating the cardioprotective effects of liraglutide in diabetic cardiomyopathy remain incompletely defined. While recent studies report beneficial cardiac phenotypes, the attribution of these effects to direct cardiomyocyte receptor signaling is not yet conclusively established. This correspondence highlights uncertainties related to cell-type specificity and potential non-myocyte contributions, and emphasizes the need for rigorous cell-type resolved validation. Clarifying the cellular basis of liraglutide action is critical for accurate mechanistic interpretation and future translational applications. |
| Publish Date |
2026-07-09 06:58 |
| Citation |
Su K, Cao PY, Chen G, Wu K. Is the cellular attribution of liraglutide action in diabetic cardiomyopathy conclusive? World J Diabetes 2026; 17(7): 117243
|
| URL |
https://www.wjgnet.com/1948-9358/full/v17/i7/117243.htm |
| DOI |
https://doi.org/10.4239/wjd.117243 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
